Bojesen SE - Search Results

1

C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease.

Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Dahl M, et al. Among authors: bojesen se. Am J Respir Crit Care Med. 2007 Feb 1;175(3):250-5. doi: 10.1164/rccm.200605-713OC. Epub 2006 Oct 19. Am J Respir Crit Care Med. 2007. PMID: 17053205

2

Integrin beta3 Leu33Pro homozygosity and risk of cancer.

Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Bojesen SE, et al. J Natl Cancer Inst. 2003 Aug 6;95(15):1150-7. doi: 10.1093/jnci/djg005. J Natl Cancer Inst. 2003. PMID: 12902444

3

Platelet glycoprotein IIb/IIIa Pl(A2)/Pl(A2) homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men: the Copenhagen City Heart Study.

Bojesen SE, Juul K, Schnohr P, Tybjaerg-Hansen A, Nordestgaard BG; Copenhagen City Heart Study. Bojesen SE, et al. J Am Coll Cardiol. 2003 Aug 20;42(4):661-7. doi: 10.1016/s0735-1097(03)00781-2. J Am Coll Cardiol. 2003. PMID: 12932598 Free article.

4

No association of breast cancer risk with integrin beta3 (ITGB3) Leu33Pro genotype.

Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. Bojesen SE, et al. Br J Cancer. 2005 Jul 11;93(1):167-71. doi: 10.1038/sj.bjc.6602674. Br J Cancer. 2005. PMID: 15970922 Free PMC article.

5

Increased risk of ovarian cancer in integrin beta3 Leu33Pro homozygotes.

Bojesen SE, Kjaer SK, Høgdall EV, Thomsen BL, Høgdall CK, Blaakaer J, Tybjaerg-Hansen A, Nordestgaard BG. Bojesen SE, et al. Endocr Relat Cancer. 2005 Dec;12(4):945-52. doi: 10.1677/erc.1.01083. Endocr Relat Cancer. 2005. PMID: 16322334

6

Increased risk of breast cancer associated with CHEK2*1100delC.

Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. Weischer M, et al. Among authors: bojesen se. J Clin Oncol. 2007 Jan 1;25(1):57-63. doi: 10.1200/JCO.2005.05.5160. Epub 2006 Jul 31. J Clin Oncol. 2007. PMID: 16880452

7

Integrin beta3 Leu33Pro polymorphism and risk of hip fracture: 25 years follow-up of 9233 adults from the general population.

Tofteng CL, Bach-Mortensen P, Bojesen SE, Tybjaerg-Hansen A, Hyldstrup L, Nordestgaard BG. Tofteng CL, et al. Among authors: bojesen se. Pharmacogenet Genomics. 2007 Jan;17(1):85-91. doi: 10.1097/01.fpc.0000236327.80809.f8. Pharmacogenet Genomics. 2007. PMID: 17264806

8

Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population.

Ørsted DD, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Ørsted DD, et al. Among authors: bojesen se. J Exp Med. 2007 Jun 11;204(6):1295-301. doi: 10.1084/jem.20062476. Epub 2007 May 29. J Exp Med. 2007. PMID: 17535973 Free PMC article.

9

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.

Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. Weischer M, et al. Among authors: bojesen se. J Clin Oncol. 2008 Feb 1;26(4):542-8. doi: 10.1200/JCO.2007.12.5922. Epub 2008 Jan 2. J Clin Oncol. 2008. PMID: 18172190 Review.

10

The common germline Arg72Pro polymorphism of p53 and increased longevity in humans.

Bojesen SE, Nordestgaard BG. Bojesen SE, et al. Cell Cycle. 2008 Jan 15;7(2):158-63. doi: 10.4161/cc.7.2.5249. Epub 2007 Nov 1. Cell Cycle. 2008. PMID: 18256523

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

370 results

Search Page

Filters